Condition: Respiratory Syncytial Virus Infection · Sponsor: Simcere Pharmaceutical Co., Ltd
This is a randomized, double-blind, placebo-controlled, parallel-group trial conducted in infants and young children aged 1 to 36 months with RSV infection. A total of 498 subjects are expected to be enrolled and randomly assigned to the investigational product group or the placebo group in a 2:1 ratio; Administration will be based on the subject's weight, with a dose of 20 mg/kg three times daily for 5 consecutive days (15 doses).
This description comes directly from the study's public registry record.
zhibiao song · 86-13641133681 · songzhibiao@simcere.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital Of Xiamen University | Xiamen, Fujian, China | Recruiting |
| Hunan Children's Hospital | Changsha, Hunan, China | Recruiting |
| West China Second University Hospital Sichuan University | Chengdu, Sichuan, China | Not Yet Recruiting |
| Shulan(hangzhou)Hospital | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07402512